UP2: Brain Controlled Spinal Cord Stimulation in Participants With Cervical Spinal Cord Injury for Upper Limb Rehabilitation

Sponsor
Ecole Polytechnique Fédérale de Lausanne (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05665998
Collaborator
(none)
3
1
25

Study Details

Study Description

Brief Summary

Cervical spinal cord stimulation can elicit arm and hand movements through recruitment of proprioceptive neurons in the dorsal roots. In participants with cervical spinal cord injury, the spare roots bellow the lesion can be used to reactivate motor function. Decoding of motor intentions can be achieved through implantable electrocorticography (ECoG) devices.

In this study, the investigators will use an investigational system using ECoG signal recording over the motor cortex to drive muscle specific electrical epidural spinal cord stimulation (EES). The investigators will assess the safety and preliminary efficacy of this system in 3 participants.

Condition or Disease Intervention/Treatment Phase
  • Device: ARC-BSI Cervical system
N/A

Detailed Description

In a current first-in-human clinical trial, called STIMO, Electrical Epidural Spinal Stimulation (EES) is applied to enable individuals with chronic severe spinal cord injury (SCI) to complete intensive locomotor neurorehabilitation training. In this clinical feasibility study, EES triggered an immediate enhancement of walking function, and was integrated in an intensive neurorehabilitation program. This therapy improved leg motor control and triggered neurological recovery in individuals with severe SCI to a certain extent (Wagner et al. 2018, Kathe et al. 2022).

Concurrently, preclinical and clinical evidence demonstrated a similar recruitment of upper limb muscles through cervical spinal cord stimulation, re-triggering arm movements after paralysis. The spatial and temporal modulation of the electrical stimulation can selectively activate muscle groups towards a specific function.

Clinatec (CEA, Grenoble, France) has developed an implantable electrocorticogram (ECoG) recording device with a 64-channel epidural electrode array capable of recording electrical signals from the motor cortex for an extended period and with a high signal to noise ratio. This ECoG-based system allowed tetraplegic patients to control an exoskeleton (Clinicaltrials.gov, NCT 02550522) with up to 8 degrees of freedom for the upper limb control (Benabid et al., 2019). This device has been implanted in 4 individuals so far; one of them has been using this system both at the hospital and at home for more than 3 years.

Another ongoing clinical study: STIMO-BSI (Brain Spine Interface) (Clinicaltrials.gov:

NTC04632290), is combining the EES and ECoG technology to allow leg motor control in patients with chronic SCI through the decoding of cortical signals.

In this study, the investigators will test the safety and preliminary efficacy of ECoG-controlled EES in individuals with cervical SCI and establish a direct bridge between the participants' motor intention and the spinal cord below the lesion, which could restore voluntary control of arm movements as well as promote neurological recovery when combined with neurorehabilitation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
3 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
single-site, single-arm, non-blinded, non-randomized, interventionalsingle-site, single-arm, non-blinded, non-randomized, interventional
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Brain Controlled Spinal Cord Stimulation in Participants With Cervical Spinal Cord Injury for Upper Limb Rehabilitation (UP2)
Anticipated Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Mar 31, 2025
Anticipated Study Completion Date :
Mar 31, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: ARC-BSI Cervical Rehabilitation

Implantation of a neuroprosthetics system composed of an electrocorticography acquisition system (WIMAGINE) and a cervical epidural electrical spinal cord stimulation system (ARC-IM) to restore voluntary arm movements in participants with SCI.

Device: ARC-BSI Cervical system
Unilateral implantation of a 64 channel - ECoG array over the sensory motor cortex combined with an implantation of 32 channel spinal cord stimulation system over the cervical region. The system decodes the motor attempts of the participant and translates those intentions into modulation of electrical stimulation.

Outcome Measures

Primary Outcome Measures

  1. Number of treatment-related serious adverse events (SAEs). [Through completion of the study 12 months]

Secondary Outcome Measures

  1. Graded and Redefined Assessment of Strength Sensibility, and Prehension (GRASSP) score [7 months]

    0-232 points, higher score indicating better performance

  2. Action Research Arm Test (ARAT) score [7 months]

    0-57 points, higher score indicating better performance

  3. Capabilities of the Upper Extremity Test (CUE-T) [7 months]

    0-68 points, higher score indicating better performance

  4. Range of Motion (in rad) [7 months]

  5. Grasp force (in N) [7 months]

  6. Pinch force (in N) [7 months]

  7. International Standards for Neurological Classification of SCI (ISNCSCI) score [7 months]

    0-324 points, higher score indicating better function

  8. Maximum voluntary contraction (in N.m) [7 months]

  9. Somato-sensory evoked potential amplitude (in mV) [7 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
  • Must provide Informed Consent as documented by signature (Appendix Informed Consent Form),

  • Must be at least 18 years old and no older than 75 years old at the time of enrolment,

  • Must be suffering from non-progressive traumatic cervical spinal cord injury,

  • Must be graded A, B, C, or D in the American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification,

  • Must be severely impaired in his upper limb function as determined by the investigator,

  • Must have sustained the injury at least 6 months before signing the consent form,

  • Must be able to understand and interact with the study team in French or English,

  • Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments.

  • Must use safe contraception for women of childbearing capacity,

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Ecole Polytechnique Fédérale de Lausanne

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Jocelyne Bloch, Certified neurosurgeon, head of functional neurosurgery, Ecole Polytechnique Fédérale de Lausanne
ClinicalTrials.gov Identifier:
NCT05665998
Other Study ID Numbers:
  • UP2
First Posted:
Dec 27, 2022
Last Update Posted:
Dec 27, 2022
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jocelyne Bloch, Certified neurosurgeon, head of functional neurosurgery, Ecole Polytechnique Fédérale de Lausanne
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 27, 2022